Immuto Scientific has raised an $8 million Seed 2 financing round, led by DYDX, the company announced recently.

According to a release, the funds will be used to advance Immuto Scientific’s internal oncology pipeline toward IND-enabling studies and extend the platform into additional areas such as immunology and inflammation.

Other participants included WARF Ventures, Gravity Fund and Great Oaks Venture Capital.

Immuto Scientific also announced its drug discovery collaboration with Daiichi Sankyo, a global pharmaceutical company.

“Our collaboration with Daiichi Sankyo underscores how exploring the structural conformations of cell‑surface proteins represents an untapped frontier in drug discovery,” Immuto Scientific CTO Dan Benjamin said in a statement. “By targeting cancer‑specific surface structures, we have the opportunity to develop first‑in‑class therapies with truly differentiated precision and selectivity.”

The two companies will look to discover new targets in solid tumors using their proprietary structural surfaceomics platform and to develop antibodies against these targets.

Financial terms of the agreement were not disclosed.